Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 2
2016 2
2018 4
2019 17
2020 16
2021 16
2022 8
2023 13
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
Advances in Immunotherapy for Hepatocellular Carcinoma (HCC).
Bicer F, Kure C, Ozluk AA, El-Rayes BF, Akce M. Bicer F, et al. Among authors: akce m. Curr Oncol. 2023 Nov 7;30(11):9789-9812. doi: 10.3390/curroncol30110711. Curr Oncol. 2023. PMID: 37999131 Free PMC article. Review.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Nonsurgical Management of Rectal Cancer.
Akce M, El-Rayes BF. Akce M, et al. J Oncol Pract. 2019 Mar;15(3):123-131. doi: 10.1200/JOP.18.00769. J Oncol Pract. 2019. PMID: 30861368 Review.
NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, Javle MM, Cleary SP, Akce M, Switchenko JM, Rocha FG. Maithel SK, et al. Among authors: akce m. Ann Surg Oncol. 2023 Oct;30(11):6558-6566. doi: 10.1245/s10434-023-13809-5. Epub 2023 Jun 27. Ann Surg Oncol. 2023. PMID: 37368098 Free PMC article. Clinical Trial.
Frontline therapy for advanced hepatocellular carcinoma: an update.
Akce M, El-Rayes BF, Bekaii-Saab TS. Akce M, et al. Therap Adv Gastroenterol. 2022 Apr 11;15:17562848221086126. doi: 10.1177/17562848221086126. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 35432597 Free PMC article. Review.
The Potential of CAR T Cell Therapy in Pancreatic Cancer.
Akce M, Zaidi MY, Waller EK, El-Rayes BF, Lesinski GB. Akce M, et al. Front Immunol. 2018 Sep 25;9:2166. doi: 10.3389/fimmu.2018.02166. eCollection 2018. Front Immunol. 2018. PMID: 30319627 Free PMC article. Review.
68 results